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Summary Thirty-four cases of ductal carcinoma in situ (DCIS) of the breast, with or without associated
benign or invasive disease, were anlaysed for allelic imbalance (Al) in the region of the BRCAJ gene. AI on
17ql2-23 in DCIS was demonstrated in 74% of cases, and in the majority of cases the region of Al included
the BRCA1 gene. However, two cases showed Al distal to BRCA1, supporting the presence of a second
tumour-suppressor gene on 17q.
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Mutations of the BRCA1 gene on chromosome 17q21 are
thought to be responsible for a proportion of inherited breast
cancers (Miki et al., 1994). Many of the other tumour-
suppressor genes originally identified as a result of their
involvement in familial cancers are known to be mutated in
sporadic tumours. There has, therefore, been much interest in
the involvement of BRCAJ in sporadic forms of breast
cancer. Loss of heterozygosity (LOH), which suggests the
inactivation of a tumour-suppressor gene (Ponder, 1988), has
been demonstrated in the vicinity of the BRCAI locus in
breast tumours by a number of groups (Futreal et al., 1992;
Cornelis et al., 1993; Cropp et al., 1993; Borg et al., 1994).
However, the majority of the cases studied have been invasive
tumours, and the involvement of the BRCAJ gene in the
earlier stages of sporadic breast tumour development has not
yet been specifically addressed.
The analysis of early preinvasive lesions not only allows
the identification of genetic alterations that might be
initiating events in tumorigenesis, but, when compared with
alterations occurring in invasive carcinoma from the same
patient, allows important conclusions to be drawn regarding
the stepwise progression of breast tumours. The relationship
between preinvasive breast lesions and invasive carcinoma is
at present unclear. Epidemiological studies have shown that
patients with atypical epithelial hyperplasia and with
carcinoma in situ are at increased risk of developing invasive
breast cancer (Rosen et al., 1980; Dupont and Page, 1985;
Tavassoli and Norris, 1990). In particular, patients with
ductal carcinoma in situ (DCIS) have a substantial risk, and
circumstantial evidence suggests that it may be a precursor
lesion (Betsill et al., 1978; Page et al., 1982). There is little
molecular data regarding the nature of DCIS, as genetic
analysis is mainly restricted to tumour material microdis-
sected from paraffin-embedded tissue sections. However, we
and others have demonstrated that a number of genetic
alterations occurring in invasive carcinomas are also present
in DCIS, namely c-erbB-2 amplification, TP53 mutation and
allelic loss on chromosomes 1, 7, 16 and 17p (Liu et al., 1992;
Radford et al., 1993; Munn et al., 1995, 1996; Stratton et al.,
1995). In this present study we have used polymerase chain
reaction (PCR) amplification of microsatellite polymorphisms
to address the involvement of the BRCA1 gene in cases of




Nineteen cases of DCIS were obtained from Glenfield
Hospital, Leicester, three of which had an associated area
of frank invasive carcinoma. A further 16 cases were
obtained from Christie Hospital, Manchester, consisting of
12 cases with DCIS and associated invasive carcinoma; three
cases with an additional benign proliferative component,
DCIS and invasive carcinoma; and one case with a benign
proliferative component and invasive carcinoma. For all cases
the histological classification (Table 1) was confirmed by a
histopathologist (RAW and LM). The nuclear grades of the
DCIS were determined based on nuclear size, pleomorphism
and mitoses. All tumour samples were formalin fixed and
paraffin embedded, and for the majority of cases a block
containing normal breast tissue was also available.
Microdissection and DNA extraction
Normal tissue and areas of DCIS and benign proliferative
material or invasive carcinoma when present, were micro-
dissected from haematoxylin-stained 5 or 10 ,um sections, and
DNA was extracted as previously described (Munn et al.,
1995). In all cases epithelial cells were microdissected and
analysed and there was minimal contamination by stromal or
inflammatory cells.
Analysis of microsatellite polymorphisms
The following polymorphisms were analysed on chromosome
17q: Mfdl5 (D17S250), Mfdl88 (D17S579), 42D6 (D17S588)
and GH. The oligonucleotides used were described by Weber
et al. (1990); Polymeropoulos et al. (1991); Hall et al. (1992)
and Cornelis et al. (1993) respectively. In addition intragenic
TP53 polymorphisms and polymorphisms at 17pl3.3 were
used to control for allele loss on chromosome 17p, as
described by Munn et al. (1996). Normal and tumour DNA
were analysed as previously described by Munn et al. (1995),
except that the amplification conditions were as follows:
4 min at 94°C followed by 35 cycles of 1 min at 94°C, 1 min
at 55°C, 1 min at 72°C, and a final extension at 72°C for
10 min. Allelic imbalance (Al) was determined in hetero-
zygotes as a reduction in intensity of one allele relative to the
other in the tumour sample according to criteria described by
Hoggard et al. (1995). The data were confirmed by analysing
the dried gels using a phosphorimager (Molecular Dynamics
425S).
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Results
Of 34 cases of DCIS that were informative for at least one
marker on chromosome 17q, Al was demonstrated in 24
(74%, Table 2, Figure 1). However, in three of these cases, in
which separate areas of DCIS were studied, Al was seen in
tumour isolated from one area but not in the other. In eight
cases (24%) showing Al on chromosome 17q, Al was also
observed at all informative markers studied at l7pl3,
suggesting possible loss of a whole copy of chromosome 17.
This was observed both in cases with only DCIS and in those
with an associated area of invasive carcinoma. A further
eight cases (24%), all examples of comedo DCIS, showed Al
at all informative markers on 17q while retaining hetero-
zygosity at markers on 17p, suggesting possible loss of the
long arm of the chromosome. The remaining cases showing
Al on chromosome 17q showed a pattern consistent with an
interstitial deletion or possible telomeric deletion. In seven of
these cases this overlaps with the region between D17S250
and D17S579 in which the BRCAJ gene is known to map.
However, two cases (15 and 34) showed retention of both
alleles at Dl 7S579 but showed Al at the distal marker
D17S588. In both cases clear loss of an allele was observed,
consistent with the presence of a second tumour-suppressor
gene on 17q, distal to BRCAJ. Of those 18 cases in which
both DCIS and invasive carcinoma were present, the same
pattern of Al was observed in 12 (67%). Of the remaining six
cases, four showed Al in the invasive component but not in
the DCIS. Two cases (3041 and 5170) showed loss of
different alleles in each component (Figure 1c). In 12 cases
two independent areas of DCIS were analysed. Six of these
cases showed a different pattern of alteration in each area
(Figure lb) with one other case (1565) showing loss of
different alleles. Of the three cases in which a benign
component, DCIS and invasive carcinoma were present,
two cases (1565 and 2996) showed Al only in the DCIS and
invasive tumour, whereas case 6457 showed Al in all three
components. A single case contained only a benign lesion and
invasive tumour (6045) and showed Al in the papilloma but
not in the invasive carcinoma (Figure ld). This case had been
described as having a DCIS component, but it was not
possible to find DCIS on the section available and so this was
not studied.
Discussion
This study demonstrates a high frequency of involvement of
the long arm of chromosome 17q in DCIS. Whether the
putative tumour-suppressor gene BRCAJ is the target of the
observed Al remains unclear. Since the cloning of BRCAI no
somatic mutations of the gene have been found in sporadic
Table I Histology of tumours studied. Series 1 comprises those samples in which DCIS is present alone, series 2 those in which is an additional
benign or invasive component


















Series 2 DCIS and invasive carcinoma
452 Micropapillary + ID Low (II)
458 Cribriform +ID High (III)
593 Cribriform +ID Low (I)
982 Cribriform +ID Intermediate (II)
1141 Cribriform+ID nd (III)
1565 Florid hyperplasia, comedo+ID Intermediate (II)
2753 Cribriform/solid +ID Low (II)
2822 Cribriform + ID Low (II)
2939 Cribriform + ID Intermediate (II)
2996 Sclerosing adenosis, comedo + ID High (III)
3041 Cribriform +tubular carcinoma Low (I)
4410 Comedo+ID High (III)
4617 Comedo/micropapillary + ID High (III)
4681 Cribriform/papillary + ID Intermediate (II)
5170 Comedo + ID High (III)
6045b Papilloma, comedo+ID Intermediate (II)
6256 Cribriform +ID Low (II)
6384 Comedo + ID Intermediate (II)
6457 Fibroadenosis, comedo + ID High (III)
Nuclear grade ofDCIS was classified according to van Dongen et al. (I1992) as low, intermediate or high. For samples in series 2, the grade of the
invasive component is given in parentheses when known, and was assessed according to Elston and Ellis (1991). b Sample 6045 was classified as
comedo DCIS adjacent to invasive, with papilloma present. On the section we obtained there was no DCIS; therefore, only the papilloma and
invasive cells were studied (see Table II).BRCA1 in ductal carcinoma in situ
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Table II Results of Al studies at chromosome 17q12 - 23; the BRCA1 gene is known to map between D17S250 and D17S579
Case 6 15 34 56 75 106 144 257 1886 2281 3410 3800 3805 4119 4736 4753
Series 1:
Locus C12 MP C MP C12 Crl2 C12 C Cr12 C12 C CrC C12 C C12 C12
D17S250 00 - @ 0 @ *O 0 0 0* 0 @0 0 00 00 - 00 00
D17S579 0 000 *0 0 0 0 0 0
D17S588 000 0 00 0 00000 0 0000 00
GH 0 0 0 0 *0 00 0 0 - 0 - 0 -
Series 2.
Case 452 458 593 982 1141 1565 2753 2822 2939 2996 3041 4410 4617 4681 5170 6045 6256 6384 6457
Locus MPI Crl Crl Crl Cr I BC1 21 Cr1 Crl Cr1 B C I CrI CI MPI P Cr I C I B I Cr I C I B C I
D17S250 00000 00 OOOO o0 o oo o00 oo000 00 *OO- *O - O 0
D17S579 00 00 00 -O* *Q
D17S588 - 00 - - - - 0000 00 000 00o 0 00 o
GH 00 - 0000 00 0- 0 - 00 - 00 00
0, Informative and both alleles retained; 0, Informative and showing allelic imbalance; , Not informative i.e. homozygous; no symbol, not
tested due to lack offurther tumour material/sample consistently failed to amplify at that marker; t, different allele retained; C, comedo DCIS; Cr,















Figure 1 Autoradiographic examples of Al on 17q in cases of
DCIS, with or without an associated area of invasive carcinoma.
(a) Al in the cribriform component of case 106. (b) Al with loss
of the same alleles in both the comedo and invasive components
of case 1565. In contrast, the second area of comedo DCIS from
the same tumour shows loss of the other allele. (c) Al in the
comedo component but not the invasive tumour of case 5170. (d)
Al in the papilloma but not the invasive component of case 6045.
N, normal tissue; C, comedo DCIS; Cr, cribriform DCIS; I,
invasive carcinoma; B, papilloma.
breast tumours to date (Futreal et al., 1994), although there
are recent reports of mutations in sporadic ovarian tumours
(Merajver et al., 1995). If BRCAJ is not involved in sporadic
breast tumour development this may be because the wild-type
product acts at a stage of breast development that precedes
sporadic tumour initiation. There are however a number of
other genes in the vicinity of BRCAJ that are possible targets
of deletion in sporadic breast tumours, despite the fact that
they were eliminated as candidates for BRCA1; for example
NM23 and PHB (prohibitin) (Leone et al., 1991; Sato et al.,
1992; Royds et al., 1993), alterations to both of which have
been previously demonstrated in sporadic breast tumours. In
addition the c-erbB-2 gene maps between Dl 7S250 and
D17S579. Overexpression of c-erbB-2 has frequently been
observed in breast tumours and this is generally thought to
be due to gene amplification. A number of the cases of DCIS
showing Al at the BRCAI region in this study have
previously been shown to overexpress c-erbB-2 (R Walker,
unpublished). However, the patterns of Al observed in these
tumours were suggestive of allele loss rather than gain.
Therefore, if c-erbB-2 is amplified in these cases the amplicon
must be on the remaining homologue, indicating the presence
of multiple alterations on chromosome 17q in these cases. In
addition, two cases were found to show Al at a region
independent from BRCAJ, suggesting a second tumour-
suppressor gene on 17q. This has been reported previously by
several groups (Cornelis et al., 1993; Cropp et al., 1993).
The finding that 12 out of 18 cases with both DCIS and
invasive tumour show the same pattern of Al in each
component suggests that DCIS can progress to invasive
carcinoma. That this is not the case for all DCIS is clear
from those cases showing distinct alterations in both
components. This is complicated further by the heterogeneity
present within DCIS. Whatever the target of the Al observed
in this study, it is clear from those cases with DCIS and
invasive components that its alteration can occur early or late
in the development of breast tumours.
Four of the cases reported here contained benign lesions
(1565, 2996, 6045 and 6457), and two of these showed Al on
17q. In neither case was Pagetoid spread considered a
possibility, and in both cases only epithelial cells were
analysed. In case 6457 (fibroadenosis + comedo DCIS +
invasive tumour) the same pattern of Al was seen in all three
components. However in 6045, Al was only observed in the
papilloma and not in the invasive cells (DCIS cells were not
present on the sections made available to us and were
therefore not studied). The finding of a case that shows Al in
a papilloma but not in the associated invasive tumour
questions the importance of changes to sequences on 17q
for malignant transformation. Alterations to 17q present in
the later stages of tumour development might contribute to
malignancy by co-operating with other changes such as TP53
mutations. Their role in benign lesions remains to be
elucidated.
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